| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $317,614 ) |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 11/6/2023 | $18,566 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 11/6/2023 | $55,411 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL124015 | Latexin function in the maintenance and regeneration of the hematopoietic system | 001 | 8 | NIH | 11/16/2023 | $67,537 |
| | 2024 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AR079766 | Autophagic regulation of inflammasome-mediated hyperactive state in living macrophages | 001 | 3 | NIH | 11/8/2023 | $176,100 |
|
| Issue Date FY: 2023 ( Subtotal = $8,144,532 ) |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 000 | 4 | NIH | 7/1/2023 | $3,103,662 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120 | 000 | 11 | NIH | 8/25/2023 | $777,449 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 000 | 1 | NIH | 8/10/2023 | $815,643 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 001 | 2 | NIH | 3/2/2023 | $92,043 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 2 | NIH | 12/28/2022 | $828,377 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI171525 | Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury | 001 | 2 | NIH | 6/23/2023 | $213,500 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 7/19/2023 | $97,500 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 7/19/2023 | $338,232 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 000 | 3 | NIH | 5/3/2023 | $719,415 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AR079766 | Autophagic regulation of inflammasome-mediated hyperactive state in living macrophages | 002 | 3 | NIH | 2/9/2023 | $85,400 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL155574 | Hormetic ER Stress Regulation of Hematopoietic Stem Cell Function | 000 | 3 | NIH | 5/11/2023 | $495,320 |
| | 2023 | 2023 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL124015 | Latexin function in the maintenance and regeneration of the hematopoietic system | 001 | 8 | NIH | 6/30/2023 | $427,000 |
| | 2023 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 000 | 10 | NIH | 8/16/2023 | $0 |
| | 2023 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 000 | 10 | NIH | 8/16/2023 | $0 |
| | 2023 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AR079766 | Autophagic regulation of inflammasome-mediated hyperactive state in living macrophages | 001 | 3 | NIH | 2/3/2023 | $165,160 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01DK032094 | Red Cell Membrane Studies | 000 | 33 | NIH | 4/10/2023 | $0 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI078314 | The development of a recombinant vaccine against human onchocerciasis | 000 | 10 | NIH | 1/26/2023 | $0 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI078314 | The development of a recombinant vaccine against human onchocerciasis | 000 | 10 | NIH | 1/26/2023 | $0 |
| | 2023 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL140625 | Use of forward Genetic approaches to identify Babesia receptors | 000 | 4 | NIH | 9/27/2023 | -$7,978 |
| | 2023 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI124260 | Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination | 000 | 5 | NIH | 3/29/2023 | -$4,250 |
| | 2023 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL130139 | Mechanisms controlling transfusion-associated antibody responses in SCD alloimmunization | 000 | 5 | NIH | 5/15/2023 | -$35 |
| | 2023 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI137790 | A novel and effective nanobody to prevent and treat Zika virus infection | 000 | 2 | NIH | 6/9/2023 | -$1,906 |
|
| Issue Date FY: 2022 ( Subtotal = $7,083,850 ) (Continued on the next page) |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01MH118960 | Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC | 002 | 4 | NIH | 6/7/2022 | $78,799 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL155574 | Hormetic ER Stress Regulation of Hematopoietic Stem Cell Function | 000 | 2 | NIH | 5/18/2022 | $495,320 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 000 | 1 | NIH | 9/13/2022 | $804,000 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 1 | NIH | 2/25/2022 | $846,806 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 001 | 2 | NIH | 5/11/2022 | $719,415 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 000 | 3 | NIH | 6/16/2022 | $3,103,662 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01MH118960 | Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC | 001 | 4 | NIH | 2/21/2022 | $212,918 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01MH118960 | Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC | 000 | 4 | NIH | 2/7/2022 | $709,175 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 001 | 10 | NIH | 4/22/2022 | $58,083 |
| | 2022 | 2022 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 | 000 | 10 | NIH | 2/3/2022 | $792,805 |
| | 2022 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI139092 | Structure-based design of coronavirus subunit vaccines | 001 | 4 | NIH | 3/3/2022 | -$102,509 |
| | 2022 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 000 | 1 | NIH | 5/10/2022 | $0 |
| | 2022 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI137472 | Rational design and evaluation of novel mRNA vaccines against MERS-CoV | 002 | 4 | NIH | 3/3/2022 | -$339,869 |
| | 2022 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL145451 | Patrolling Monocytes in Sickle Pain Crisis and following Transfusion | 001 | 3 | NIH | 7/13/2022 | -$3,668 |
| | 2022 | 2021 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL145451 | Patrolling Monocytes in Sickle Pain Crisis and following Transfusion | 000 | 3 | NIH | 2/22/2022 | $0 |
| | 2022 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL130139 | Mechanisms controlling transfusion-associated antibody responses in SCD alloimmunization | 000 | 5 | NIH | 7/13/2022 | -$19 |
| | 2022 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI157975 | Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses | 000 | 1 | NIH | 3/3/2022 | -$74,984 |
| | 2022 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI139092 | Structure-based design of coronavirus subunit vaccines | 003 | 3 | NIH | 3/4/2022 | $0 |
| | 2022 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI139092 | Structure-based design of coronavirus subunit vaccines | 000 | 3 | NIH | 3/3/2022 | -$71,858 |
| | 2022 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01AI137472 | Rational design and evaluation of novel mRNA vaccines against MERS-CoV | 001 | 3 | NIH | 3/3/2022 | -$142,418 |
| | 2022 | 2020 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI124260 | Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combination | 000 | 5 | NIH | 8/25/2022 | -$1,808 |
|
